Clinical Oncology

[Long-term central venous access devices in oncology]


DECEMBER 10, 2016

Clinical Oncology - 2016;3(04)

[Long-term central venous access devices are essential in the management of oncology patients, as they minimize the discomfort caused by frequent venipuncture and cannulation. Indications of application of central venous accesses, possibilities of implantations, immediate and long term complications, they prevention and obviation has been reported based on guidelines and relevant publications. Long term implantable central venous accesses handled by well-trained and exercised team, working with principles of maintenance, these manipulations are effective and safe, therefore suitable in oncological practice.]



Further articles in this publication

Clinical Oncology

[Side-effects of immunotherapy]


[The immune system has an important role in controlling and eradicating cancer cells. Antibody therapy against several negative immunologic regulators (checkpoints) has demonstrated promise in a variety of malignancies. The immune checkpoint blockade with antibodies against cytotoxic T lymphocyte- associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) and its ligand have a unique and distinct pattern of adverse events. Immune-related adverse events are most commonly observed in the skin, gastrointestinal tract, liver and the endocrine system. Early recognition and treatment are believed to be important in mitigating severity of such adverse effects.]

Clinical Oncology

[Individualized treatment of advanced/metastatic adult soft tissue sarcomas]

SZŰCS Zoltan, JONES L. Robin

[Considering the extreme histological heterogeneity of soft tissue sarcomas (STS), their management is an art of its own. Over the last decade the treatment of STSs has been slowly shifting towards a more individualized, histology driven tailored approach. With the availability of novel antineoplastic agents and the differential sensitivity of different subtypes of sarcomas to these drugs, we aim to provide some guidance in terms of optimal sequencing of therapies. Furthermore, we discuss some of the emerging targeted therapies currently evaluated for the palliative treatment of the more common and some of the very rare STS subtypes.]

Clinical Oncology

[Treatment of anemia in cancer patients]


[Anemia in cancer can be resulted by the underlying malignant disease or related to the chemotherapy. Cancer-related anemia adversely effects quality of life and is associated with reduced survival. Clinical studies demonstrate that blood transfusions, ESAs, and correction of iron defi ciency are therapeutic options for anemic cancer patients.]

Clinical Oncology


A szerkesztők

Clinical Oncology

[News from the World]

All articles in the issue

Related contents

Lege Artis Medicinae

[A modern approach to the surgical treatment of osteoarthritis of the hip]


[The authors review the development of surgical treatment of osteoarthritis of the hip, including the joint preserving interventions for biomechanical reconstruction in prearthroses, and the joint deceasing, or joint replacing procedures in advanced osteoarthritis. Demonstrating the indications, contraindications and possible complications they point to the responsibility of the surgeon, and to the changes of the recent strategy comparing to the previous one. They give a „state of the art” description regarding the surgical treatment of osteoarthritis of the hip supported by references from the literature and their own experience.]

Hungarian Radiology

[Metal objects in the MR]


[During magnetic resonance imaging the patient is exposed to three different types of electromagnetic radiation: static magnetic field, gradient or time varying magnetic fields and radiofrequency electromagnetic fields. The potential risks associated with performing MRI in patients with ferromagnetic implants, materials, or devices are related to the possibility of movement or dislodgement, to the induction of electrical currents and to the heating. The majority of metallic implants are considered to be safe for MRI, but patients with cardiac pacemakers, ferromagnetic aneurysm clips, cochlear implants, implantable drug infusion pumps should not be examined by MRI.]

Clinical Neuroscience

[Initial clinical experience with radio-frequency assisted percutaneous vertebral augmentation in the treatment of vertebral compression fractures]


[Purpose - Percutaenous Vertebroplasty (PVP) is effective in alleviating pain and facilitating early mobilization following vertebral compression fractures. The relatively high risk of extravertebral leakage due to uncontrolled delivery of low viscosity bone cement is an inherent limitation of the technique. The aim of this research is to investigate the ability of controlled cement delivery in decreasing the rate of such complications by applying radiofrequency heating to regulate cement viscosity. Method and material - Thirty two vetebrae were treated in 28 patients as part of an Ethics Committee approved multicenter clinical trial using RadioFreqency assisted Percutaenous Vertebral Augmentation (RF-PVA) technique. This technique is injecting low viscosity polymethylmethacrylate (PMMA) bone cement using a pressure controlled hydraulic pump and applying radiofrequency heating to increase cement viscosity prior to entering the vertebral body. All patients were screened for any cement leakage by X-ray and CT scan. The intensity of pain was recorded on a Visual Analog Scale (VAS) and the level of physical activiy on the Oswestry Disability Index (ODI) prior to, one day, one month and three months following procedure. Results - All procedures were technically successful. There were no clinical complication, intraspinal or intraforaminal cement leakage. In nine cases (29%) a small amount of PMMA entered the intervertebral space through the broken end plate. Intensity of pain by VAS was reduced from a mean of 7.0 to 2.5 and physical inactivity dropped on the ODI from 52% to 23% three months following treatment. Conclusion - In this small series controlled cement injection using RF-PVA was capable of preventing clinically hazardous extravertebral cement leakage while achieving outcomes similar to that of conventional vertebroplasty.]

Lege Artis Medicinae

[Efficacy and safety of sitagliptin during long term treatment in patients with type 2 diabetes]


[Due to the progressive nature of the type 2 diabetes mellitus and treatment requires prolonged lifestyle and/or pharmacologic management, the long term efficacy, durability and safety of newer antihyperglycemic agents are important considerations. Metformin is the most common prescribed oral antihyperglycemic agent (OHA) for initial therapy. Often, initial single oral agent is not sufficient to maintain good glucose control, combination of OHA are usually required to manage patients with type 2 diabetes. Incretinbased therapies (e.g. dipeptidyl peptidase 4 (DPP 4) inhibitors and analogues of glucagon like peptide 1) are newer compounds available for the treatment of type 2 diabetes. Sitagliptin is a once-daily OHA with a novel mechanism of action that targets the incretin axis. Addition of sitagliptin to ongoing metformin therapy was well tolerated and resulted in significant glycemic improvement after 30-104 weeks of treatment in patients with type 2 diabetes.]

Clinical Neuroscience



[Purpose - To evaluate the efficacy and safety of gabapentin (GBP) in idiopathic or crypto/symptomatic partial epilepsy in adults. Methods - We performed a prospective open label add-on study in pharmacoresistant patients with simple or complex partial or generalized seizures of partial onset (at least four seizures per month). GBP was added to no more than two baseline antiepileptics and the efficacy was rated primarily according to the seizure frequency. The secondary efficacy parameters were the change in the seizure severity scores (measured by the NHS3 scale) and in the quailty of life (measured by the QUOLIE-31 questionnaire). GBP was added up to 1500-1600 mg per day in the titration period than an individual optimalization was allowed in any further visits. The follow-up period was three months. Population - Fourteen Hungarian epilepsy out-patient unit participated in the study. 72 patients were enrolled, GBP was applied in 63 persons (ITT population) and 57 completed the study. Results - A more than 50% decrease in seizure frequency was found in more than 70% of the patients in the third month. Among them just every third patient became seizure-free. Significant improvement appeared also in the severity of seizures and in the total score of the quality of life questionnaire. There was no difference either according to the etiology of the epilepsy or the seizure types. GBP was tolerated excellently. There was no need to decrease of the dosage of GBP and the side effects were mild and of transitory nature. Consequences - GBP appears to be a valuable antiepileptic drug considering its high efficacy and extremely favourable tolerance. While GBP also decreases the severity of the seizures, its complex effects result an improvement in the quality of life of the patients. The positive effects have been durable during the follow-up. Open label naturalistic studies of larger population are needed to clear the special indications of GBP in chronic partial epilepsies.]